Clinical Effects of Whole Body Gamma Knife Combined with Pemetrexed Plus Carboplatin on Concurrent Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

Objective To evaluate the clinical effects and adverse reactions of whole body gamma knife combined with pemetrexed plus carboplatin on concurrent chemoradiotherapy for locally advanced non-small cell lung cancer(LANSCLC). Methods Total 42 cases of LANSCLC patient were selected.They included ⅢA stage NSCLC(18 cases) and ⅢB stage NSCLC(24 cases)；adenocarcinoma (26 cases) and squamous carcinoma (16 cases).All of the patients underwent whole body gamma knife combined with pemetrexed plus carboplatin in concurrent chemoradiotherapy (pemetrexed 500 mg/m2 and carboplatin AUC=5 were administrated to the patients on the first day of every three-weeks for four cycles.) Clinical efforts and adverse reactions were evaluated. Results The response rate (CR+PR) was 85.7%，The 1-，2-year survival rates and the median survival periods were 76.2%,45.2%，18.6 months,respectively；All the adverse reactions were between gradeⅠ～Ⅲ,which were mainly bone marrow suppression，gastrointestinal reactions and radiation esophagitis.No grade Ⅳ adverse reaction had been occurred.Leukopenia was occurred in 5 cases (11.9%） of grade Ⅲ. Conclusion Whole body gamma knife combined with pemetrexed plus carboplatin in concurrent chemoradiotherapy has a relatively good short and remote effectiveness，with good safety and tolerability.